What is Brawn Biotech Ltd (530207) share price return in the past 10 years?

Brawn Biotech Ltd share price has declined -7.4% annually (CAGR) over the past ten years.

What is the share price of Brawn Biotech Ltd (530207)?

Company share prices are keep on changing according to the market conditions. The current trading price of Brawn Biotech Ltd (530207) on 10-Apr-2026 16:59:59 at 16:59 is 20.48.

What is the P/E ratio of Brawn Biotech?

The latest standalone P/E ratio of Brawn Biotech as of 10-Apr-2026 is 0.00.

What is the P/B ratio of Brawn Biotech Ltd (530207)?

The latest standalone P/B ratio of Brawn Biotech Ltd (530207) as of 10-Apr-2026 is 1.64.

What is the 52-week high and low of Brawn Biotech Ltd (530207)?

The 52-week high of Brawn Biotech Ltd (530207) is Rs. 24.37 and the 52-week low is Rs. 15.70.

Brawn Biotech Ltd (530207) Share Analysis – Quality, Valuation Zone & Price Trend & DeciZen Rating

Name: Brawn Biotech Ltd (530207)
Brand: Brawn Biotech

Brawn Biotech Ltd (530207) Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating

Key Metrics

Market Cap

₹6 Cr.

P/E Ratio

0.00

Price to Book (P/B)

1.64

Price to Sales (P/S)

0.36

EV/EBITDA

-541.42

Return on Capital Employed (ROCE)

-42.59%

Current Price

₹20.5

Return on Equity (ROE)

-41.30%

Return on Assets (ROA)

-10.20%

Operating Profit Margin

-13.2%

Net Profit Margin

-12.92%

Gross Profit Margin

-12.5%

Book Value per Share

₹12.5

Sales Growth (YoY)

-18.31%

Sales Growth (3 Years)

16.04%

Operating Profit Growth (1 Year)

NA%

Operating Profit Growth (3 Years)

N/A%

Net Profit Growth (1 Year)

NA%

52-Week Low / High

₹16 / 24

Net Profit Growth (3 Years)

N/A%

Dividend Yield

0.00%

Promoter Holding

52.94%

Pledged shares (%)
of Promoter's holding (%)

0.00%

Check Before You Invest

Q.1

Brawn Biotech Ltd belongs to the Miscellaneous sector, operating specifically within the Trading segment.

Q.1 Gross Profit margin of Brawn Biotech Ltd?

Brawn Biotech Ltd Gross profit margin which is the profit after deduction of direct costs, is -12.5% for FY-2025 , which is below its 5 year median of 0% , indicating decreasing margins.

Q.1 Promoter shareholding and pledge status of Brawn Biotech Ltd?

Promoters hold 52.94% of the Brawn Biotech Ltd, with 0.00% of their stake pledged, indicating no pledge risk.

Q.1 Revenue growth of Brawn Biotech Ltd vs industry peers?

Brawn Biotech Ltd revenue CAGR is -22.96% , compared to the industry median CAGR of 17.75% , indicating slower growth and losing its market share.

Q.1 Stock return of Brawn Biotech Ltd over the last decade?

Over the last 9 years, the stock has delivered a CAGR of -7.9% based on the current price.

Q.1 Is Brawn Biotech Ltd a good quality company?

Brawn Biotech Ltd is a quality company, based on a 10 year financial track record .

DeciZen - make an informed investing decision on Brawn Biotech

Based on:

Data

M-Cap below 100cr DeciZen not available

Brawn Biotech stock performance

Key Ratios

Is Brawn Biotech Ltd an attractive stock to invest in?

1. Is Brawn Biotech Ltd a good quality company?

Past 10 year's financial track record analysis by Moneyworks4me indicates that Brawn Biotech Ltd is a average quality company.

2. Is Brawn Biotech Ltd undervalued or overvalued?

The key valuation ratios of Brawn Biotech Ltd's currently when compared to its past seem to suggest it is in the Fair zone.

3. Is Brawn Biotech Ltd a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Brawn Biotech Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

10 Year X-Ray :

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

Value Creation Index Colour Code Guide ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
ROCE % ⓘ	26.4%	29%	27.8%	23%	9.7%	-3.6%	-25.7%	-5.9%	-26.1%	-42.6%	-
Value Creation Index ⓘ	0.9	1.1	1.0	0.7	-0.3	-1.3	-2.8	-1.4	-2.9	-4.0	-
Growth Parameters ⓘ Growth Parameters Colour Code Guide ⓘ
Sales ⓘ	46.9	60.6	55.8	65.2	49.6	35	8.6	22.2	16.5	13.5	17
Sales YoY Gr.	-	29.2%	-7.9%	16.9%	-23.9%	-29.5%	-75.4%	157.9%	-25.8%	-18.3%	-
Adj EPS ⓘ	3.3	3.3	4.2	4.1	1.8	-2.5	-5.5	-2.9	-4.1	-5.8	-0.5
YoY Gr.	-	0.3%	26.3%	-1%	-57.7%	-241.1%	NA	NA	NA	NA	-
BVPS (₹) ⓘ	18.4	23.1	25.4	28.9	30.9	29.3	24.1	21	16.9	11.2	12.5
Adj Net Profit ⓘ	1	1	1.3	1.2	0.5	-0.7	-1.7	-0.9	-1.2	-1.7	-0
Cash Flow from Ops. ⓘ	0.1	1.4	-1.5	0.2	-0.1	0	0.2	0.3	-0	0.1	-
Debt/CF from Ops. ⓘ	2.4	0	0	0	0	0	0	0	0	0	-

CAGR ⓘ

CAGR Colour Code Guide ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	-12.9%	-23%	16%	-18.3%
Adj EPS ⓘ	-206.5%	-227.1%	NA	NA
BVPSⓘ	-5.4%	-18.3%	-22.5%	-33.6%
Share Price	-7.4%	-2.2%	7.5%	16.9%

Key Financial Parameters ⓘ

Performance Ratio Colour Code Guide ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
Return on Equity % ⓘ	18.9	15.9	17.2	15.3	5.9	-8.2	-20.6	-12.8	-21.8	-41.3	-3.9
Op. Profit Mgn % ⓘ	3.2	2.1	3.5	1.8	1.5	-1.7	-23.3	-1.4	-8.9	-13.2	-2.2
Net Profit Mgn % ⓘ	2.1	1.6	2.3	1.9	1.1	-2.1	-19.1	-3.9	-7.5	-12.9	-0.8
Debt to Equity ⓘ	0	0	0	0	0	0	0	0	0	0	-
Working Cap Days ⓘ	105	85	120	122	152	171	545	214	298	443	272
Cash Conv. Cycle ⓘ	28	31	32	27	46	70	274	57	99	185	94

Recent Performance Summary

Sales growth is growing at healthy rate in last 3 years 16.04%

Sales growth is good in last 4 quarters at 17.13%

Return on Equity is Poor

Latest Financials

	Standalone	Consolidated
TTM EPS (₹)	-0.5	-
TTM Sales (₹ Cr.)	17.3	-
BVPS (₹) ⓘ	12.5	-
Reserves (₹ Cr.) ⓘ	1	-
P/BV ⓘ	1.64	-
PE ⓘ	0.00	-

From the Market
52 Week Low / High (₹)	15.70 / 24.37
All Time Low / High (₹)	0.40 / 95.60
Market Cap (₹ Cr.)	6.1
Equity (₹ Cr.)	3
Face Value (₹)	10
Industry PE ⓘ	24.2

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged ^*

0.00

* Pledged shares as % of Promoter's holding (%)

Valuation of Brawn Biotech - Standalone Basis

YTD 1Y 3Y 5Y 10Y Max

Analyst's Notes

No data found!

Key Ratios

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Sales	46.88	60.55	55.78	65.18	49.62	34.98	8.62	22.23	16.49	13.46
Operating Expenses ⓘ +	45.45	59.31	53.82	64.01	48.88	35.57	10.63	22.53	17.97	15.24
Manufacturing Costs	0.20	0.06	0.06	0.08	1.28	1.41	0.19	0.34	0.20	0.12
Material Costs	40.52	52.19	48.85	58.50	42.10	30.02	6.59	19.18	14.36	11.93
Employee Cost	1.86	1.98	2.98	3.02	3.08	2.36	1.80	1.40	1.40	1.13
Other Costs ⓘ	2.86	5.08	1.93	2.41	2.41	1.78	2.04	1.62	2.01	2.06
Operating Profit ⓘ	1.44	1.24	1.96	1.17	0.74	-0.60	-2.01	-0.30	-1.47	-1.77
Operating Profit Margin (%)	3.1%	2.0%	3.5%	1.8%	1.5%	-1.7%	-23.3%	-1.4%	-8.9%	-13.2%
Other Income ⓘ +	0.01	0.62	0.09	0.74	0.17	0.31	0	0.01	0.09	0.09
Exceptional Items ⓘ	0	0	0	0	0	0	0	0	0	0
Interest ⓘ	0.11	0.07	0.06	0.07	0.05	0.04	0.06	0.01	0.06	0
Depreciation ⓘ	0.03	0.03	0.03	0.03	0.03	0.03	0.05	0.11	0.10	0.11
Profit Before Tax ⓘ	1.30	1.76	1.96	1.81	0.82	-0.36	-2.12	-0.41	-1.54	-1.80
Tax ⓘ	0.36	0.36	0.68	0.47	0.23	0.19	-0.47	0.46	-0.30	-0.06
Profit After Tax	0.95	1.39	1.28	1.33	0.59	-0.55	-1.64	-0.87	-1.25	-1.74
PAT Margin (%)	2.0%	2.3%	2.3%	2.0%	1.2%	-1.6%	-19.1%	-3.9%	-7.6%	-12.9%
Adjusted EPS (₹)	3.2	4.6	4.3	4.4	2.0	-1.8	-5.5	-2.9	-4.2	-5.8
Dividend Payout Ratio (%)	32%	32%	23%	0%	0%	0%	0%	0%	0%	0%

Balance Sheet

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Equity and Liabilities
Shareholders Fund +	5.53	6.92	7.63	8.66	9.26	8.80	7.22	6.31	5.07	3.36
Share Capital ⓘ	3	3	3	3	3	3	3	3	3	3
Reserves ⓘ	2.53	3.92	4.63	5.66	6.26	5.79	4.22	3.31	2.06	0.36
Debt +	0.05	0	0	0	0	0	0	0	0	0
Long Term Debt	0.05	0	0	0	0	0	0	0	0	0
Short Term Debt	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
Trade Payables	4.95	6.82	11.23	10.35	8.59	2.66	4.05	6.47	5.67	8.24
Others Liabilities ⓘ	3.40	3.25	3.63	3.45	2.37	2.27	1.89	1.59	3.39	8.37
Total Liabilities ⓘ	13.93	16.98	22.49	22.45	20.22	13.72	13.16	14.37	14.13	19.97
Fixed Assets
Net Fixed Assets ⓘ +	0.24	0.25	0.22	0.19	0.18	0.14	0.39	0.37	0.33	0.46
Gross Block	0.32	0.36	0.36	0.36	0.38	0.38	0.67	0.77	0.78	1.02
Accumulated Depreciation	0.08	0.10	0.14	0.17	0.20	0.24	0.29	0.40	0.45	0.56
CWIP ⓘ	0	0	0	0	0	0	0	0	0	0
Investments ⓘ	0.03	0	0	0	0	0	0	0	0	0
Inventories	0.50	0.37	0.35	0.34	0.39	0.26	4.72	4.79	6.02	10.47
Trade Receivables	9.20	13.02	15.05	16.46	15	9.28	2.81	5.32	3.88	3.41
Cash Equivalents	0.17	2	0.40	0.54	0.40	0.40	0.22	0.44	0.40	0.20
Others Assets ⓘ	3.79	1.34	6.47	4.92	4.26	3.65	5.02	3.45	3.50	5.43
Total Assets ⓘ	13.93	16.98	22.49	22.45	20.22	13.72	13.16	14.37	14.13	19.97

Cash Flow

(All Figures are in Crores.)

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Cash Flow From Operating Activity ⓘ +	0.05	1.37	-1.54	0.21	-0.08	0.03	0.19	0.32	-0.03	0.05
PBT ⓘ	1.30	1.76	1.96	1.81	0.82	-0.36	-2.12	-0.41	-1.54	-1.80
Adjustment ⓘ	0.13	2.20	0.09	0.15	0.10	0.15	0.19	0.07	0.06	0.16
Changes in Working Capital ⓘ	-1.02	-1.83	-2.31	-0.93	-0.76	0.51	2.12	0.65	1.46	1.69
Tax Paid ⓘ	-0.36	-0.76	-1.29	-0.82	-0.23	-0.28	0	0.01	0	0
Cash Flow From Investing Activity ⓘ +	-0.08	0.57	-0	-0	-0.02	0	-0.30	-0.10	-0.01	-0.24
Capex	0	-0.03	-0	-0	-0.02	0	-0.30	-0.10	-0.01	-0.24
Net Investments	0	0	0	0	0	0	0	0	0	0
Others ⓘ	-0.08	0.61	0	0	0	0	0	0	0	0
Cash Flow From Financing Activity ⓘ +	-0.05	-0.11	-0.06	-0.06	-0.05	-0.04	-0.06	-0.01	-0	-0
Net Proceeds from Shares ⓘ	0	0	0	0	0	0	0	0	0	0
Net Proceeds from Borrowing ⓘ	0.05	-0.05	0	0	0	0	0	0	0	0
Interest Paid ⓘ	-0.10	-0.07	-0.06	-0.06	-0.05	0	-0.06	-0.01	-0	-0
Dividend Paid ⓘ	0	0	0	0	0	0	0	0	0	0
Others ⓘ	0	0	0	0	0	-0.04	0	0	0	0
Net Cash Flow ⓘ	-0.08	1.83	-1.60	0.15	-0.14	-0	-0.17	0.21	-0.04	-0.20

Finance Ratio

PARTICULARS	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25
Ratios
ROE (%)	18.15	22.39	17.62	16.37	6.6	-6.1	-20.53	-12.83	-21.93	-41.3
ROCE (%)	26.39	29.04	27.75	23.03	9.74	-3.57	-25.66	-5.94	-26.12	-42.59
Asset Turnover Ratio	3.36	3.92	2.83	2.9	2.33	2.06	0.64	1.61	1.16	0.79
PAT to CFO Conversion(x)	0.05	0.99	-1.2	0.16	-0.14	N/A	N/A	N/A	N/A	N/A
Working Capital Days
Receivable Days	72	67	92	88	116	127	256	67	102	99
Inventory Days	6	3	2	2	3	3	105	78	120	223
Payable Days	53	41	67	67	82	68	186	100	154	213

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Brawn Biotech Ltd FAQs

The current trading price of Brawn Biotech on 10-Apr-2026 16:59 is ₹20.48.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 09-Apr-2026 the market cap of Brawn Biotech stood at ₹6.14 Cr

The latest P/E ratio of Brawn Biotech as of 09-Apr-2026 is 0.00.

The latest P/B ratio of Brawn Biotech as of 09-Apr-2026 is 1.64.

The 52-week high of Brawn Biotech is ₹24.37 and the 52-week low is ₹15.70.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Brawn Biotech is ₹17.26 ( Cr.) .

About Brawn Biotech Ltd

Brawn Pharmaceuticals was incorporated in the year 1985 it operates in health care sector in India and outside India. It has started its business by selling pharmaceutical formulations manufactured by other companyâ€™s loan license basis. The company is located in New Delhi, India.

Business Profile:

The company involves in the manufacture, contract manufacture, and supply of pharmaceutical products. It is basically engages in the manufacture of tablets, capsules, and oral syrups.

Products of the company

Company's products are made under various categories namely Analgesics, Antibiotics, Anti Tuberculosis, Anti-inflammatory, Antipyretic, Anti Malarial, B Complex and Amino Acids, Cardiovascular drugs, Antiphyscotropic drugs, Tranquilizers, Antacids.

You have 0 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now

Build a Stress-Tested Portfolio.

Our Sapphire Advisory uses the ABC Concept to ensure you never have to panic during a market correction.

Core Stocks

STABILITY

Booster Stocks

GROWTH

Amplifier Stocks

ASYMMETRY

● Conflict-Free ● SEBI Registered ● 15Y+ Track Record

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Brawn Biotech Ltd (530207) Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating

Brawn Biotech Share Price